Erythromycin Lactobionate
Who holds supplier records for Erythromycin Lactobionate? 3 organisations hold a current record for Erythromycin Lactobionate: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (3).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Erythromycin Lactobionate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/erythromycin-lactobionate
Reading the evidence
- 3 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
3 of the 3 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 2 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (3)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Erythromycin Lactobionate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 34072 · latest filing Aug 2019
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 34750 · latest filing Sept 2020
- GLAND PHARMA LTDIndia Company GMP cert on recordActive DMF 34426 · latest filing Dec 2019
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Overview
Erythromycin Lactobionate is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1200506).
Chemical identity
- IUPAC name
- (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid
- Canonical SMILES
- CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)O)O)O)O)O)O)O
- InChIKey
- NNRXCKZMQLFUPL-WBMZRJHASA-N
- Synonyms
- Erythrocin, Erythromycini lactobionas, Erythromycin lactobionate, Sterile erythromycin lactobionate, Erythrocin Lactobionate, RefChem:55127, n-2,10-dion(1:1), Erythromycin lactobionate (1:1) (salt), Erythromycin lactobionate [JAN], EINECS 223-348-7, Erythrocin Lactobionate IV, Erythromycin lactobionate [USP:BAN:JAN]
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Macrolide; Macrolide Antimicrobial
- Physiologic effect
- Decreased Sebaceous Gland Activity
- Chemical structure
- Macrolides
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Erythromycin Lactobionate?
3 organisations hold an active US FDA Type II Drug Master File or a CEP for Erythromycin Lactobionate: APITORIA PHARMA PRIVATE LTD (India), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India) and GLAND PHARMA LTD (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Erythromycin Lactobionate Drug Master Files are active?
APITORIA PHARMA PRIVATE LTD (DMF 34072), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 34750) and GLAND PHARMA LTD (DMF 34426). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
How do I qualify a Erythromycin Lactobionate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Erythromycin Lactobionate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.